Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2015

Open Access 01-12-2015 | Research article

Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years

Authors: Leif Öhlin, Mats Fridell, Anna Nyhlén

Published in: BMC Psychiatry | Issue 1/2015

Login to get access

Abstract

Background

A seven-year follow-up of heroin dependent patients treated in a buprenorphine-maintenance program combining contracted work/education and low tolerance for non-prescribed drug use. Gender-specific differences in outcome were analysed.

Methods

A consecutively admitted cohort of 135 men and 35 women, with eight years of heroin abuse/dependence on average was admitted to enhanced buprenorphine maintenance treatment. Standardized interviews, diagnostic assessments of psychiatric disorders and psychosocial conditions were conducted at admission and at follow-ups. Outcome associated with gender was reported for abstinence, retention, psychiatric symptoms, employment and criminal convictions.

Results

148 patients started treatment. After seven years, 94/148 patients (64%) were retained in the program, employed and abstinent from drugs and alcohol. Women had more continuous abstinence, retention and employment than men (76% versus 60%). After one year patients with a high-risk consumption of alcohol were no longer heavy consumers of alcohol and remained so throughout the study (p < .001). All women regained custody of their children.
At admission, more women than men had been admitted for psychiatric disorders (70%/44%) and to compulsory care for substance abuse (30%/18%). Initial gender differences of psychiatric co-morbidity decreased and were no longer significant after one year.
More men than women had been imprisoned (62% versus 27%) or in non-institutional care (80% versus 49%). Criminal convictions were reduced from 1751 convictions at admission to 742 (58%) after seven years.
Eight patients in the entire cohort died over the 7 years (0.7% per year). One patient died in the completers group while still in the program (0.1% per year).

Conclusions

After seven years, two thirds of the patients in the program were abstinent and employed. Convictions ceased in the completers group. One patient died in the completers group.
Women had superior long-term outcome compared to men: more continuous abstinence, employment and fewer convictions. Women also lived with their children to a higher extent than men.
The positive outcome highlights the importance of maintaining high structure in combining pharmacological treatment with a focus on employment and psychological treatment and low tolerance for non-prescribed drug use.
Literature
1.
Swedish Council for the information on Alcohol and Other Drugs. Drogutvecklingen i Sverige: Rapport 2011. [Drug development in Sweden: Report 2011]. Stockholm: CAN; 2012.
2.
SOU 2011:35: Swedish government inquiries. Bättre insatser vid missbruk och beroende-Individen, kunskapen, ansvaret: [Better Response to Abuse and Addiction: Individual, Knowledge, Responsibility.]. Stockholm: Department of Health and Social Affairs; 2011.
3.
Vaillant GE. A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry. 1973;29:237–41.CrossRefPubMed
4.
Hser Y-I, Hoffman V, Grella CE, Anglin D. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503–8.CrossRefPubMed
5.
Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alc Dependence. 1995;40:139–50.CrossRef
6.
Fridell, M. Drogmissbrukare med psykisk störning – femårsuppföljning av tunga narkomaner, in Swedish. [Drug misusers with co-morbid psychiatric disorder]. I Gerdner, A., & Sundin, Ö (Red:er): Dubbel trubbel – Nya rön och erfarenheter i diagnos och behandling av samtidigt beroende och psykisk störning [Double trouble - New experiences in diagnostics and treatment of co-morbid substance abuse]. Örebro, Runnagården, 1998.
7.
Fridell, M, Billsten, J, Jansson I, & Hesse M. 15-årsuppföljning av drogberoen-de personer. [15-year follow-up of drug dependence] I B. Fries & F. Nyberg (Red:er). Vad vet vi om narkotikaanvändarna i Sverige? [What do we know about narcotic users in Sweden ?] MoB-rapport no 14, 2006, Sid 21–27
8.
Romelsjö A, Engdahl B, Stenbacka M, Fugelstad A, Davstad I, Leifman A, et al. Were the changes to Sweden’s maintenance treatment policy 2000–06 related to changes in opiate-related mortality and morbidity? Addiction. 2010;105(9):1625–32.CrossRefPubMed
9.
Berglund M, Thelander S, Jonsson E. Treatment of alcohol and drug abuse. Evidence-based review. Darmstadt: Wiley, VCH Gmbh & Co KGaA; 2003.CrossRef
10.
Ling W, Wessen DR, Charauvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401–7.CrossRefPubMed
11.
Strain E, Stitzer I, Liebso I, Bigelow G. Comparison of Buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025–30.CrossRefPubMed
12.
Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The Summit trial: a field comparison of Buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–52.CrossRefPubMed
13.
Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone versus Buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5.CrossRefPubMedPubMedCentral
14.
Fridell M. Institutionella Behandlingsformer vid Missbruk: Ideologi. Organi-sation och resultat [Institutional Treatment Methods in Substance Abuse - Ideology, Organization and Results. Stockholm, Natur och Kultur, 1996, Chapt. 4, Pp 118–146.
15.
Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;4(10):949–58.CrossRef
16.
Hättenschwiler J, Ruesch P, Hell D. Effectiveness of inpatient drug detoxifi-cation: links between process and outcome variables. Eur Addict Res. 2000;6:123–31.CrossRefPubMed
17.
The Swedish Council on Technology Assessment in Health Care (SBU): [in Swedish]. Treatment of alcohol and drug problems - an evidence based review. Stockholm: SBU; 2001.
18.
Kakko J. Improving maintenance treatment of heroin addiction: The role of buprenorphine. In: PhD thesis. Stockholm: Karolinska Institutet; 2009.
19.
The National Board of Health and Welfare. Nationella riktlinjer för missbruks- och beroendevården: Vägledning för Socialtjänsten och Hälso-/sjukvårdens verksamhet för personer med missbruks- och beroendeproblem. [Swedish National Guidelines for Treatment of Substance Abuse and Dependence.]. Stockholm: The National Board of Health and Welfare; 2007.
20.
SOSFS 2009:27 (M). Läkemedelsassisterad underhållsbehandling vid opiat-beroende. [Medication-assisted treatment for opiate dependence.] The National Board of Health and Welfare. Stockholm; 2009.
21.
Nyhlén A, Fridell M, Hesse M, Krantz P. Causes of premature mortality in Swedish drug abusers: a prospective longitudinal study 1970–2006. J Forensic Legal Med. 2011;18:66–72.CrossRef
22.
Stenbacka M, Leifman A, Romelsjö A. Mortality and cause of death among 1705 illicit drug users: a follow up. Drug Alcohol Rev. 2010;29(1):21–7.CrossRefPubMed
23.
Grönbladh L, Öhlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–7.CrossRefPubMed
24.
Bukten A, Skurtveit S, Gossop M, Waal H, Stangeland P, Havnes I, et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2011;107:393–9.CrossRefPubMed
25.
Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction. 2007;102(3):406–12.CrossRefPubMed
26.
Warner-Smith M, Darke S, Lynsky M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96(8):1113–25.CrossRefPubMed
27.
Alho H, Sinclair D, Vouri E, Holooainen A. Abuse liability of buprenorphine tablets in untreated IV drug users. Drug Alcohol Depen. 2007;88(1):75–8.CrossRef
28.
Fugelstad A. Akuta narkotikarelaterade dödsfall 1994 – 2010. [Development of acute drug-related deaths 1994–2010.] Karolinska Institutet. Institute of Clinical Neuroscience. Swedish National Institute of Public Health. Stockholm; 2012.
29.
Grant BF, Stinson FS, Dawson DA, Chou AP, Ruan J, Pickering RP. Co-occurrence or 12-Month Alcohol and Drug Use Disorders and Personality Disorders in the United States. Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:361–8.CrossRefPubMed
30.
Jansson I. Femårsuppföljning av tvångsvårdade kvinnor: Inverkan av psykiska problem på utfallet. [Five-Year Follow-up Compulsory Care Women: Impact of Mental Health Problems on the Outcome.] PhD Thesis. Department of Psychology. University of Lund; 2010.
31.
Fridell, M. Personlighet och drogmissbruk – En forskningsöversikt. [Personality and drug abuse – A research overview.] CAN 1991, PM-series 10, Stockholm.
32.
Uchtenhagen U, Zieglgänsberger W. Suchtmedizin - Konzepte, Straegien und therapeutisches Management [Addiction medicine - concepts, strategies and therapeutical management]. Munchen: Urban & Fischer Verlag; 2000.
33.
Fridell M, Hesse M, Jæger M, Kühlhorn E. Antisocial personality disorders as predictor of criminal behaviour in a longitudinal study of a cohort of abusers of several classes of drugs: Relation to type of substance and type of crime. Addict Behav. 2008;33:799–811.CrossRefPubMed
34.
Verheul V. Co-morbidity of personality disorders in individuals with substance use disorders. Eur Psychiatry. 2001;16:274–82.CrossRefPubMed
35.
Fridell M, Billsten J, Jansson I, Amylon R. Femårsuppföljning: kvinnor vårdade vid Lundens ungdomshem och LVM-hem. [Five-year Follow-up of Women treated at Lundens Youth and LVM home.]. Stockholm: Statens institutionsstyrelse; 2009.
36.
Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry. 1999;14(7):366–71.CrossRefPubMed
37.
Sörensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand. 2005;111:244–9.CrossRefPubMed
38.
Hodgins S, Tengström A, Bylin S, Göranson L, Hagen L, Jansson M, et al. Consulting for Substance Abuse: mental disorders among adolescents and their parents. Nordic J Psychiatry. 2007;61(5):379–86.CrossRef
39.
Berglund GW, Bergmark B, Björling B, Grönbladh L, Lindberg S, Oscarsson L, et al. The SWEDATE project: Interaction between treatment, client background and outcome in a one-year follow-up. J Subst Abuse Treat. 1991;8(3):161–9.CrossRefPubMed
40.
Johnsson E, Fridell M. Suicide attempts in a cohort of drug abusers: a 5-year follow-up study. Acta Psychiatr Scand. 1997;96(5):362–6.CrossRefPubMed
41.
Byqvist S. Patterns of drug use among drug misusers in Sweden Gender differences. Subst Use Misuse. 2006;41(13):1817–35.CrossRefPubMed
42.
Greenfield S, Brooks A, Gordon S, Green C, Kropp F, McHugh R, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86:1–21.CrossRefPubMed
43.
Jansson I, Fridell M. Psykisk och somatisk belastning hos LVM- och LVU- vårdade. SiS följer upp och utvecklar 1. [Psychological and somatic stress of LVM and LVU nursed women at Lunden.] SiS follow-up and develops 1. Stockholm: Statens institutionsstyrelse; 2003.
44.
Nordberg L, Rydelius P-A, Zetterström R. Children of alcoholic parents: Health, growth, mental development and psychopathology until school age. Acta Paediatr Scand. 1993;387:1–24.CrossRef
45.
Bergman LR, Wångby M. Are girls more than boys subjected to disrupted conditions of upbringing? Scand J of Soc Welfare. 1998;7:194–203.CrossRef
46.
Nilsson KW, Alm PO, Leppert J, Oreland L, Sjöberg RL, Ohrvik J. Interaktioner mellan gener och miljö. Predicerar kriminalitet, depression och alkohol-beroende. [Interactions between genes and milieu. Predicts criminality, depression and alcohol dependence.]. Lakartidningen. 2006;39(103):2859–62.
47.
Ljungberg B, Christensson B, Tunving K, Andersson B, Landvall B, Lundberg M, et al. HIV prevention among injecting drug users: Three years of experiences from a syringe exchange program in Sweden. J Acquir Immune Defic Syndr. 1991;4(9):890–5.CrossRefPubMed
48.
Isaksson A, Walter L, Hansson T, Andersson A, Alling C. Phosphatidylethanol in blood (B-Peth): a marker for alcohol use and abuse. Drug Test Anal. 2011;3(4):195–200.CrossRefPubMed
49.
McLellan AT, Kushner H, Metsger D, Peters R, Smith L, Grissom G, et al. The fifth edition of the addiction severity index. J Substance Abuse Treatm. 1992;9(3):199–213.CrossRef
50.
Anderberg M, Dahlberg M. Strukturerade intervjuer inom missbruksvården som grund för kunskapsutveckling. [Structured Interviews in Drug Treatment as a Basis for Knowledge dissemination.] PhD thesis. Växjö: Växjö University, Institutionen för vårdvetenskap och socialt arbete; 2009.
51.
Gustavsson JP, Bergman H, Edman G, Ekselius L, von Knorring L, Linder J. Swedish Universities Scales of Personality – SSP: Construction, Internal Consistency, and Normative Data. Acta Psych Scand. 2000;102:201–2009.CrossRef
52.
Kranzler HR, Tennen H, Babor TF, Kadden RM, Rounsaville B-J. Validity of the longitudinal, expert, all data procedure for psychiatric diagnosis in patients with psychoactive substance use disorders. Drug Alcohol Depend. 1997;45:93–104.CrossRefPubMed
53.
Ottosson H, Bodlund O, Ekselius L, Grann M, von Knorring L, Kullgren G, et al. DSM-IV and ICD-10 personality disorders: a comparison of a self-report questionnaire (DIP-Q) with a structured interview. Eur Psychiatry. 1998;13(5):246–53.CrossRefPubMed
54.
Derogratis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale – preliminary report. Psychopharmacol Bull. 1973;9:13–28.
55.
Fridell M, Cesarec Z, Johansson M, Malling Andersson T. Svensk normering, standardisering och validering av Symtomskalan SCL-90. [Swedish Norms,Standardization and Validation of the Symptoms Checklist 90]. Stockholm: SIS; 2002.
56.
Antonovsky A. The structure and properties of the sense of coherence rating scale. Soc Sci Med. 1999;36(6):725–33.CrossRef
57.
Hansson K, Olsson M. Känsla av sammanhang - ett mänskligt strävande. [Sense of coherence - a human striving]. Nordisk Psykologi. 2001;53(3):238–55.
58.
Olsson M, Hansson K, Cederblad M. A follow-up study of adolescents with condict disorder: Can long-term outcome be predicted from psychiatric assessment data? Nord J Psychiatry. 2008;62:121.CrossRefPubMed
59.
Bergman H, Källmén H. Alcohol use among Swedes and a psychometric evaluation of the alcohol use disorders identification test. Alcohol Alcoholism. 2001;37(3):245–51.CrossRef
60.
Saunders JB, Aasland OG, Babor TF, De La Fuente JR, Grant M. Development of the alcohol use disorder identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791–804.CrossRefPubMed
61.
SCB. Central Bureau of statistics. Befolkningsstatistik. [Statistical Population.]. Stockholm: SCB; 2012.
62.
Öhlin L, Hesse M, Fridell M, Tätting P. Poly-substance use and antisocial personality traits at admission predict cumulative retention in a Buprenorphine programme with mandatory work and high compliance profile. BMC Psychiatry. 2011;11:81.CrossRefPubMedPubMedCentral
63.
The National Board of Health and Welfare. Kartläggning av läkemedels-assisterad behandling vid opiatberoende. [Mapping of medication-assisted treatment for opioid dependence]. Stockholm: The National Board of Health and Welfare; 2012.
64.
Fugelstad A, Johansson I, Thiblin I. Allt fler dör av metadon. “Läckage” från dagens mer liberal behandlingsprogram kan vara en orsak. [Increasing numbers are dying of methadone. “Leakage” from today’s more liberal treatment can be a cause]. Lakartidningen. 2010;107(18):1225–8.PubMed
65.
Grönbladh L. A National Swedish Methadone Programme1966-1989. PhD thesis. Acta Universitatis Upsaliensis. Faculty of Medicine nr. 1325. Uppsala; 2004.
66.
Darke S, Hall W. Levels of correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend. 1995;39:231–5.CrossRefPubMed
67.
Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007;26(1):55–63.CrossRefPubMed
68.
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharma Col. 2010;35(1):217–38.CrossRef
69.
Kakko J, von Wachenfeldt J, Dybrandt Svanberg K, Lidström J, Barr C, Heilig M. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008;63(2):172–7.CrossRefPubMed
70.
Gunne L, Grönbladh L, Öhlund L. Treatment characteristics and retention in methadone maintenance: High and stable retention rates in a Swedish two-phase programme. Heroin Add Ref Clin Probl. 2002;4:37–45. 3.
71.
Karterud S, Wilberg T, Urnes Ö. Personlighetspsykiatri. [Personality psychiatry]. Lund & Oslo Gyldendal 2010/Studentlitteratur 2014.
Metadata
Title
Buprenorphine maintenance program with contracted work/education and low tolerance for non-prescribed drug use: a cohort study of outcome for women and men after seven years
Authors
Leif Öhlin
Mats Fridell
Anna Nyhlén
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2015
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-015-0415-z

Other articles of this Issue 1/2015

BMC Psychiatry 1/2015 Go to the issue

Research article

Reliability and validity of ADHD diagnostic criteria in the Assessment System for Individuals with ADHD (ASIA): a Japanese semi-structured diagnostic interview

Research article

An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review

Research article

What are the factors associated with depressive symptoms among orphans and vulnerable children in Cambodia?

Research article

Community-based mental health treatments for survivors of torture and militant attacks in Southern Iraq: a randomized control trial

Research article

Did female prisoners with mental disorders receive psychiatric treatment before imprisonment?

Erratum

Erratum to: The clinical and cost effectiveness of group art therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness analysis